Delving into the Latest Updates on AETAS Pharma Co., Ltd. with Synapse

Overview

Basic Info

Introduction

AETAS Pharma is a specialized pharmaceutical company that focuses on researching, developing, and licensing drugs. The company has been dedicated to discovering and developing substances that enhance cardiac and renal functions since its inception in May 2000. A key area of focus for AETAS Pharma is the development of atrial fibrillation therapeutics for heart disease, which currently lacks a definitive treatment. The company is actively working on a developed formulation to provide relief to patients suffering from this condition.

Tags

Urogenital Diseases

Cardiovascular Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

No Data

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Top 5 Drug Type	Count

Small molecule drug	3

Top 5 Target	Count

Potassium channel x RYR2 x Sodium channels x calcium channel	1
RYR1 x RYR2 x RYR3	1

Atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF) often coexist; however, clinically available anti-AF drugs can exacerbate symptoms of HFpEF. M201-A suppressed ryanodine receptor-mediated diastolic Ca²⁺ leakage, possibly inhibiting common pathological processes toward AF and HFpEF. To bridge the basic information to clinical practice, we assessed its cardiohemodynamic, anti-AF and ventricular proarrhythmic profile using halothane-anesthetized dogs (n = 4). M201-A hydrochloride in doses of 0.03, 0.3 and 3 mg/kg/10 min was intravenously administered, providing peak plasma concentrations of 0.09, 0.81 and 5.70 μg/mL, respectively. The high dose of M201-A showed various cardiovascular actions. Namely, M201-A increased mean blood pressure and tended to enhance isovolumetric ventricular relaxation without suppressing ventricular contraction or decreasing cardiac output. M201-A enhanced atrioventricular conduction, but hardy affected intra-atrial/ventricular conduction. Importantly, M201-A prolonged effective refractory period more potently in the atrium than in the ventricle, indicating that it may become an atrial-selective antiarrhythmic drug. Meanwhile, M201-A prolonged QT interval/QTcV, and showed reverse frequency-dependent delay of ventricular repolarization. M201-A prolonged J-T_peakc without prolonging T_peak-T_end or terminal repolarization period, indicating the risk of causing torsade de pointes is negligible. Thus, M201-A is expected to become a hopeful therapeutic strategy for patients having pathology of both AF and HFpEF.

01 Mar 2011·American Journal of Physiology-Heart and Circulatory PhysiologyQ2 · MEDICINE

Three-dimensional reconstruction of the human capillary network and the intramyocardial micronecrosis

Q2 · MEDICINE

Article

Author: Toda, Masashi ; Shimamoto, Ken ; Kaneko, Noboru ; Matsuda, Ryuko

Three-dimensional reconstruction of the human heart was performed to define the structure of the intramyocardial microvasculature. A total of 200 consecutive serial sections of 6 μm each were prepared from the left ventricular tissue of an autopsied human heart with normal coronary arteries. The corresponding arteriole, venule, and all capillaries were reconstructed using three-dimensional software. The capillary network extended right and left along the cardiomyocyte with major and minor axes of about 130 and 120 μm, respectively. The capillary length from an arteriole to an adjacent venule was about 350 μm. Two types of sack-like structures, the precapillary sinus and the capillary sinus, were present in the capillary network, and many capillaries diverged from these sinuses. The cardiomyocytes were covered with reticular capillaries. In contrast, the precapillary and capillary sinuses were surrounded by many cardiomyocytes. The arterial and venous capillaries were positioned alternately, forming a lattice pattern. Intramyocardial microcirculatory units forming a capillary network from an arteriole to adjacent venules on both sides were present. The sizes of myocardial micronecroses corresponded to that of the intramyocardial microcirculatory unit. These results show that the capillary network is an ordered and anatomically regulated structure and that the microcirculatory unit and the precapillary and capillary sinuses may play an important role in maintaining the intramyocardial microcirculation during contraction and relaxation.

100 Deals associated with AETAS Pharma Co., Ltd.

Login to view more data

100 Translational Medicine associated with AETAS Pharma Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 01 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

2

Phase 2 Clinical

Other

2

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

M-201 ( RYR1 x RYR2 x RYR3 )	Heart Failure More	Phase 2
JTV-519 ( Potassium channel x RYR2 x Sodium channels x calcium channel )	Atrial Fibrillation More	Phase 2
AK-14	Urinary Bladder, Overactive More	Discovery
AE-07	Pulmonary Atelectasis More	Pending
AK-10 ( troponin )	Heart Failure More	Pending